Helius (HSDT) Form 3: Director Discloses Warrants and RSUs
Rhea-AI Filing Summary
Chee Choon Wee filed a Form 3 reporting initial beneficial ownership in Helius Medical Technologies, Inc. (HSDT). The filing shows 6,830,402 shares of common stock held indirectly through Fusion Summer Limited, 6,830,402 stapled warrants exercisable from 09/18/2025 for 36 months at a $10.134 exercise price, and 1,109,118 restricted stock units granted 09/18/2025, each convertible into one share under the companys 2022 Equity Incentive Plan.
Positive
- Transparent disclosure of insider ownership and equity awards in accordance with Section 16 filings
- Large insider stake reported (6,830,402 shares indirectly), indicating alignment between executive leadership and shareholders
- Clear terms provided for stapled warrants (exercise price $10.134; exercisable beginning 09/18/2025 for 36 months) and RSU grant date (09/18/2025)
Negative
- None.
Insights
TL;DR: Initial insider disclosure shows large indirect ownership and equity incentive awards, consistent with executive alignment.
The Form 3 documents that Chee Choon Wee is both a director and a 10% owner and reports indirect beneficial ownership of 6,830,402 common shares via Fusion Summer Limited and stapled warrants with a $10.134 exercise price exercisable beginning 09/18/2025 for 36 months. The filing also discloses 1,109,118 RSUs granted on 09/18/2025 under the 2022 Equity Incentive Plan, each representing one share upon vesting. This is a routine Section 16 disclosure that establishes transparency around insider holdings and potential future share issuance upon exercise or vesting.
TL;DR: The disclosure is informative but routine; it quantifies potential dilution and confirms executive ownership.
The report quantifies current indirect holdings and contingent instruments: 6,830,402 common shares held indirectly and stapled warrants covering the same number of shares exercisable at $10.134 starting 09/18/2025 for 36 months, plus 1,109,118 RSUs representing contingent shares. These items are important for calculating insider stake and potential future dilution, but the filing itself is a standard initial ownership statement without new operational or financial data.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | STAPLED WARRANT | -- | -- | -- |
| holding | RESTRICTED STOCK UNIT AWARD | -- | -- | -- |
| holding | COMMON STOCK | -- | -- | -- |
Footnotes (1)
- Summer Wisdom Holdings Limited ("Summer Wisdom") holds all ordinary shares of Fusion Summer Limited ("Fusion Summer"). Fusion Summer holds shares of the Issuer's common stock. The Reporting Person is the Controlling Shareholder of Summer Wisdom. Summer Wisdom may be deemed to be the beneficial owner of all of the common stock held by Fusion Summer. The Reporting Person, as the Controlling Shareholder of Summer Wisdom with sole power to exercise investment discretion, may be deemed to be the beneficial owner of all of the common stock held by Fusion Summer. The Reporting Person is the Issuer's Executive Chairman of its Board of Directors. The Stapled Warrant may be exercised only during the period beginning September 18, 2025 (the "Issue Date") of the Warrant, and ending on 5:00 p.m., New York City time, on the date that is thirty-six (36) months after the Issue Date of the Warrant. The restricted stock units (RSUs) granted on September 18, 2025, are subject to the conditions set forth in the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Helius Medical Technologies, Inc. Common Stock.
